Answers are grounded in this paper and cite their sources.
Clinical trial demonstrates a 100% objective response rate in patients with relapsed follicular lymphoma, suggesting effective disease control.
We report the outcome of patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with varnimcabtagene autoleucel (var‐cel), an academic anti‐CD19 chimeric antigen receptor (CAR) T‐cell product. Patients were included in the CART19‐BE‐01 clinical trial and a compassionate use program. Twenty‐seven patients with FL were treated. Cytokine release syndrome (any grade) occurred in 55% of patients (4% Grade ≥3). Only 1 case (4%) of Grade 1 neurotoxicity was documented. The objective response rate was 100% at Day +100 (93% complete response rate), and the 3‐year duration of response was 78%. The 3‐year progression‐free survival and overall survival were 78% and 81%, respectively. All patients developed B‐cell aplasia, and the 3‐year incidence of B‐cell recovery was 17%. In conclusion, patients with R/R FL treated with var‐cel obtained excellent disease control, with prolonged CAR T‐cell survival and manageable toxicity. This trial was registered as NCT03144583.
No takes yet. Share an insight, caveat, or question.
Martínez‐Cibrián et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: